Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8421. Children with cancer and their families believed and expected that symptom suffering was necessary to overcome cancer

Children with cancer and their families believed and expected that symptom suffering was necessary to overcome cancer Children with cancer and their families believed and expected that symptom suffering was necessary to overcome cancer | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Children with cancer and their families believed and expected that symptom suffering was necessary to overcome cancer Article Text Qualitative Children with cancer and their families believed and expected that symptom

Evidence-Based Nursing (Requires free registration)2005

8422. Oestrogen plus progestogen increased risk of breast cancer in postmenopausal wome

Oestrogen plus progestogen increased risk of breast cancer in postmenopausal wome Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Article Text Treatment Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women Free Cathy R Kessenich , RN, DSN, ARNP Statistics from Altmetric.com No Altmetric data available

Evidence-Based Nursing (Requires free registration)2005

8423. Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths

Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence on regular breast examination does not support its effectiveness for reducing breast cancer deaths Article Text Treatment Review: limited evidence on regular breast examination does

Evidence-Based Nursing (Requires free registration)2005

8424. Follow-up after treatment for breast cancer

Follow-up after treatment for breast cancer guideline-9 Information for… Search for Keyword: Submit Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update) Clinical practice guidelines for the care and treatment of breast cancer: 9. Follow-up after treatment for breast cancer (2005 update) Eva Grunfeld, Sukhbinder Dhesy-Thind, Mark Levine, for the Steering Committee on Clinical Practice Guidelines (...) for the Care and Treatment of Breast Cancer* Dr. Grunfeld is Professor of Medicine, Dalhousie University, and Director of Health Services and Outcomes Research, Cancer Care Nova Scotia, Halifax, NS. Dr. Dhesy-Thind is with the Cancer Care Ontario Juravinski Regional Cancer Centre and is Assistant Professor in the Department of Medicine, McMaster University, Hamilton, Ont. Dr. Levine is Professor in the Departments of Clinical Epidemiology and Biostatistics and of Medicine and is the Buffet Taylor Chair

CMA Infobase (Canada)2005

8427. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. 15900007 2005 05 18 2005 05 23 2016 10 17 1538-3598 293 19 2005 May 18 JAMA JAMA Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. 2367-71 Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity. To describe adverse events associated with adjuvant chemotherapy for breast (...) cancer, which led to premature termination of a clinical trial. We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et Predictifs [RAPP]-01) to compare the effectiveness of 2 chemotherapy regimens. Patients (women aged 18-70 years) had primary unilateral breast cancer and either a moderate number of positive axillary lymph nodes (< or =3) or no positive axillary lymph nodes (N0), but were at a high risk of relapse. Patients were treated at 11 French cancer

JAMA2005

8428. Radical prostatectomy versus watchful waiting in early prostate cancer.

Radical prostatectomy versus watchful waiting in early prostate cancer. 15888698 2005 05 12 2005 05 19 2009 04 16 1533-4406 352 19 2005 May 12 The New England journal of medicine N. Engl. J. Med. Radical prostatectomy versus watchful waiting in early prostate cancer. 1977-84 In 2002, we reported the initial results of a trial comparing radical prostatectomy with watchful waiting in the management of early prostate cancer. After three more years of follow-up, we report estimated 10-year results (...) . From October 1989 through February 1999, 695 men with early prostate cancer (mean age, 64.7 years) were randomly assigned to radical prostatectomy (347 men) or watchful waiting (348 men). The follow-up was complete through 2003, with blinded evaluation of the causes of death. The primary end point was death due to prostate cancer; the secondary end points were death from any cause, metastasis, and local progression. During a median of 8.2 years of follow-up, 83 men in the surgery group and 106 men

NEJM2005

8429. Adjuvant docetaxel for node-positive breast cancer.

Adjuvant docetaxel for node-positive breast cancer. 15930421 2005 06 02 2005 06 07 2013 11 21 1533-4406 352 22 2005 Jun 02 The New England journal of medicine N. Engl. J. Med. Adjuvant docetaxel for node-positive breast cancer. 2302-13 We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. We randomly assigned 1491 women with axillary node-positive breast (...) cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival

NEJM2005

8430. Erlotinib in previously treated non-small-cell lung cancer.

Erlotinib in previously treated non-small-cell lung cancer. 16014882 2005 07 14 2005 07 20 2015 11 19 1533-4406 353 2 2005 Jul 14 The New England journal of medicine N. Engl. J. Med. Erlotinib in previously treated non-small-cell lung cancer. 123-32 We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line (...) chemotherapy. Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens. The patients were stratified according to center, performance status, response to prior chemotherapy, number of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo. The median age of the 731 patients who underwent

NEJM2005

8431. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. 16236737 2005 10 20 2005 10 28 2015 11 19 1533-4406 353 16 2005 Oct 20 The New England journal of medicine N. Engl. J. Med. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. 1659-72 Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer (...) and completion of chemotherapy. This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693

NEJM2005

8432. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. 16236738 2005 10 20 2005 10 28 2015 11 19 1533-4406 353 16 2005 Oct 20 The New England journal of medicine N. Engl. J. Med. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. 1673-84 We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. The National Surgical (...) Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks

NEJM2005

8433. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. 16325695 2005 12 05 2005 12 22 2015 06 16 1474-547X 366 9501 2005 Dec 03 Lancet (London, England) Lancet Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant (...) treatment of high-risk breast cancer: results of a multicentre phase III trial. 1935-44 Breast cancer with extensive axillary-lymph-node involvement has a poor prognosis after conventional treatment. In trials with historical controls, high-dose chemotherapy produced improved outcomes. We compared an intensive double-cycle high-dose chemotherapy regimen with an accelerated conventionally dosed regimen in high-risk breast cancer in a multicentre trial. Patients with at least nine positive nodes were

Lancet2005

8434. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. 16382061 2005 12 29 2006 01 05 2014 11 20 1533-4406 353 26 2005 Dec 29 The New England journal of medicine N. Engl. J. Med. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. 2747-57 The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole (...) with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women. The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor-positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive

NEJM2005

8435. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. 16148283 2005 09 08 2005 09 16 2013 11 21 1533-4406 353 10 2005 Sep 08 The New England journal of medicine N. Engl. J. Med. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. 977-87 The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention. We randomly assigned 760 consecutive adult patients (...) with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia. Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma). An intention-to-treat analysis showed that fever was present for the duration of neutropenia in 65 percent of patients who

NEJM2005

8436. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. 15998890 2005 07 06 2005 07 12 2016 11 24 1538-3598 294 1 2005 Jul 06 JAMA JAMA Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. 47-55 Basic research and observational evidence as well as results from trials of colon polyp recurrence suggest a role for aspirin in the chemoprevention of cancer. To examine the effect (...) of aspirin on the risk of cancer among healthy women. In the Women's Health Study, a randomized 2 x 2 factorial trial of aspirin and vitamin E conducted between September 1992 and March 2004, 39 876 US women aged at least 45 years and initially without previous history of cancer, cardiovascular disease, or other major chronic illness were randomly assigned to receive either aspirin or aspirin placebo and followed up for an average of 10.1 years. A dose of 100 mg of aspirin (n=19 934) or aspirin placebo

JAMA2005

8437. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.

Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. 15998891 2005 07 06 2005 07 12 2016 10 17 1538-3598 294 1 2005 Jul 06 JAMA JAMA Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. 56-65 Basic research provides plausible mechanisms and observational studies suggest that apparently healthy persons, who self-select for high intakes (...) of vitamin E through diet or supplements, have decreased risks of cardiovascular disease and cancer. Randomized trials do not generally support benefits of vitamin E, but there are few trials of long duration among initially healthy persons. To test whether vitamin E supplementation decreases risks of cardiovascular disease and cancer among healthy women. In the Women's Health Study conducted between 1992 and 2004, 39 876 apparently healthy US women aged at least 45 years were randomly assigned

JAMA2005

8438. Capecitabine as adjuvant treatment for stage III colon cancer.

Capecitabine as adjuvant treatment for stage III colon cancer. 15987918 2005 06 30 2005 07 05 2015 11 19 1533-4406 352 26 2005 Jun 30 The New England journal of medicine N. Engl. J. Med. Capecitabine as adjuvant treatment for stage III colon cancer. 2696-704 Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment (...) for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. Disease

NEJM2005

8439. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. 15972865 2005 06 23 2005 06 28 2013 11 21 1533-4406 352 25 2005 Jun 23 The New England journal of medicine N. Engl. J. Med. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. 2589-97 We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer. We randomly assigned (...) patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen. A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern

NEJM2005

8440. Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Erlotinib in lung cancer - molecular and clinical predictors of outcome. 16014883 2005 07 14 2005 07 20 2015 11 19 1533-4406 353 2 2005 Jul 14 The New England journal of medicine N. Engl. J. Med. Erlotinib in lung cancer - molecular and clinical predictors of outcome. 133-44 A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether (...) responsiveness to erlotinib and its impact on survival were associated with expression by the tumor of epidermal growth factor receptor (EGFR) and EGFR gene amplification and mutations. EGFR expression was evaluated immunohistochemically in non-small-cell lung cancer specimens from 325 of 731 patients in the trial; 197 samples were analyzed for EGFR mutations; and 221 samples were analyzed for the number of EGFR genes. In univariate analyses, survival was longer in the erlotinib group than in the placebo

NEJM2005